Adam L. Boxer, M.D., Ph.D.
Endowed Professor in Memory and Aging
Director, AD and FTD Clinical Trials Program
Director, Neurosciences Clinical Research Unit
Department of Neurology, University of California, San Francisco

adam.boxer@ucsf.edu
http://memory.ucsf.edu/clinical-trials
https://www.rarediseasesnetwork.org/cms/artfl/
https://ftdregistry.org/

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches



***Figure 4*: Potential therapeutic targets for progressive suparnuclear palsy**
Three categories of intervention are under development. (1) Modulation of *MAPT* gene expression, with antisense oligonucleotides or splicing modulators. (2) Modulation of tau protein post-translational modifications, including phosphorylation, acetylation, and O-GlcNAc modification; degradation by the UPS and autophagy pathways; and modulation of the UPR. (3) Inhibition of tau propagation via trans-synaptic pathways or mediated by microglia. Modulating inflammation might alter tau pathology. GSK=glycogen synthase kinase. p300=acetyltransferase. UPS=ubiquitin proteasome system. UPR=unfolded protein response. NFTs=neurofibrillary tangles. *MAPT*=microtubule-associated protein tau.